Portfolio news Archives - Page 4 of 5

TOLREMO Therapeutics receives additional CHF 4.7 million financing

This second closing of CHF 4.7M is led by BioMedPartners AG and Altos Ventures AG, who are joining the previous investors Redalpine Venture Partners AG,…

Sina Kohlbrenner19.08.2020

All Portfolio news

Alentis Therapeutics appoints Dr. Roberto Iacone

Dr. Iacone is a physician-scientist with more than 15 years of experience in the life science industry. Before Alentis he was Global Head of Rare…

Sina Kohlbrenner19.08.2020

All Portfolio news

Versameb closes CHF 6 million seed round

Versameb also welcomes Dr. Klaas P. Zuideveld as Chief Development Officer. Prior to Versameb he was Vice President of Partnerships at Caris Life Sciences, and…

Sina Kohlbrenner19.08.2020

All Portfolio news

Polyneuron Pharmaceuticals granted the FDA orphan drug designation

The orphan drug designation can only be granted for treatments on rare diseases to advance the developments of safe and effective therapies and the FDA…

Sina Kohlbrenner19.08.2020

female laboratory worker looking into microscope

All Portfolio news

PharmaBiome secures CHF 1.75 million

PharmaBiome also welcomed two new board members with extensive biotech and entrepreneurial experience, all the way from founding to IPO. Dr. Thomas Meier joins PharmaBiome…

Sina Kohlbrenner19.08.2020

Female scientist working in a laboratory

All Portfolio news

T3 Pharma raises over 25 million Swiss francs

T3 Pharmaceuticals (T3 Pharma) has successfully closed a third financing round, raising over 25 million Swiss francs. According to a press release, the financing was co-led…

Emma Bulmer27.07.2020

All Portfolio news

New partner announcement: BB Pureos Bioventures

We are proud to announce that BB Pureos Bioventures has become a partner in BaseLaunch Phase II as the first venture capital fund. Anja Harmeier,…

Jérémie Meyer08.06.2020

All Portfolio news

Polyneuron recieves approval to begin clinical study

Congratulations to one of BaseLaunch’s portfolio companies, Polyneuron on their latest milestone: First clinical trial application approval. Wishing you great success with the studies later…

Jérémie Meyer11.05.2020

All Portfolio news

Anaveon raises CHF 35 million

Anaveon, a Basel-based immuno-oncology biotech, has successfully concluded a Series A financing round led by Syncona, a UK Life Sciences fund, and joined by the…

Jérémie Meyer05.03.2020

All Portfolio news

Polyneuron raises CHF 22.5 million in Series A financing

Polyneuron Pharmaceuticals, one of our portfolio companies has successfully raised 22.5 million francs in a round of financing. The Basel-based company will use the proceeds…

Jérémie Meyer04.03.2020

Portfolio news

TOLREMO Therapeutics receives additional CHF 4.7 million financing

Alentis Therapeutics appoints Dr. Roberto Iacone

Versameb closes CHF 6 million seed round

Polyneuron Pharmaceuticals granted the FDA orphan drug designation

PharmaBiome secures CHF 1.75 million

T3 Pharma raises over 25 million Swiss francs

New partner announcement: BB Pureos Bioventures

Polyneuron recieves approval to begin clinical study

Anaveon raises CHF 35 million

Polyneuron raises CHF 22.5 million in Series A financing

Useful links

Contact us

Sign up for our newsletter and event invitations

Follow us